aeglea biotherapeutics

Aeglea BioTherapeutics is a late clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Still a small company, but they are making strides to become a great company. Focusing on modulating the extremes of amino acid metabolism, we use novel engineered human enzymes to reduce amino acid toxicity in … Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. In this article we will take a look at whether hedge funds think Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) is a good investment right now. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. The process took 2+ months. They develop enzyme-based therapeutics in the field of amino acid metabolism that we believe will transform the lives of patients with inborn errors of metabolism and cancer. Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. Stock Awards: Compensation paid in the form of company equity that is structured as restricted stock. AEGLEA BIOTHERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. The Austin, Texas-based … 1 was here. Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with … Aeglea BioTherapeutics Inc. Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. a clinical-stage biotechnology company developing enzyme therapeutics for rare metabolic diseases with limited treatment options. Aeglea BioTherapeutics, Inc. (AGLE) estimates and forecasts. Aeglea BioTherapeutics price target raised to $24 from $20 at H.C. Wainwright. Prices shown are actual historical values and are not adjusted for either splits or dividends. By addressing metabolic deficiencies, we believe our therapies can help restore an element of balance to the lives of the patients and families we serve. Our wholly-owned pipeline is purposely built to deliver transformative therapeutics for multiple diseases where enzyme approaches have not previously been considered. If you experience any issues with this process, please contact us for further assistance. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually January 11-14. Hold Ratings. On March 21, 2021, Aeglea BioTherapeutics, Inc. (the "Company") entered into a license and supply agreement (the "License Agreement") with Immedica Pharma AB ("Immedica"), pursuant to which Immedica licensed the product rights for commercialization of pegzilarginase in the European Economic Area, United Kingdom, … Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency May 03, 2021 Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency Comparatively, Aeglea BioTherapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights PR Newswire - PRF Primary metrics and data points about Aeglea BioTherapeutics. Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with … Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aegle Therapeutics. Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. The Company’s product candidates are Pegzilarginase, ACN00177 and AEB5100. The all time high for this statistics is … I interviewed at Aeglea BioTherapeutics (Austin, TX) in March 2019. On the other hand Fidus Investment Corp (NASDAQ:FDUS) is the least popular one with only 5 bullish hedge fund positions. Aeglea Biotherapeutics, Inc. is located in Austin, TX, United States and is part of the Pharmaceutical Manufacturing Industry. Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people … Aeglea Biotherapeutics, Inc. has 30 total employees across all of its locations. Day's Range: $6.50 - $6.71. Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. H.C. Wainwright analyst Edward White maintained a Buy rating on Aeglea Biotherapeutics ( AGLE – Research Report) today and set a price target of $15.00. And 5 analysts are in estimates of company making revenue of $3.45 Million in the next quarter that will end on September 01, 2021. Management's presentation at Wainwright Investment Conferenceis a worthwhile listen and quickly brought me up to speed on the story here. The company’s shares closed last Monday at $7.87. The Fly. The Company is focused on developing a human enzyme therapeutics as advanced solutions for rare and other high-burden diseases. If you had invested in Aeglea BioTherapeutics stock at $9.77, your return over the last 5 years would have been -30.81%, for an annualized return of -7.1%. Current Price: $6.57. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage. View the AGLE U.S. Securities and Exchange Commission reporting information. a clinical-stage biotechnology company headquartered in the Austin that concentrates on developing human enzyme therapeutics for the treatment of rare genetic diseases and cancer. Stock split history for Aeglea BioTherapeutics since 2021. Aeglea BioTherapeutics, Inc. operates as a biotechnology company. Pros. Please see … Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. Risk Analysis. Cons. Georgiou founded GGMJD in 1999 (acquired by Maxygen in 2000), Aeglea Biotherapeutics in 2013 (NASDAQ: AGLE) and Kyn Therapeutics Inc. in 2016 (renamed Ikena Oncology, NASDAQ: IKNA). He served as Director of Aeglea Biotherapeutics and Ikena Oncology. The Company focuses on developing enzyme-based therapeutics in the field of amino acid metabolism. Aeglea BioTherapeutics, Inc. Common Stock (AGLE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. AEGLEA BIOTHERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Viewing 1 - 4 of 4 English Reviews. Georgiou founded GGMJD in 1999 (acquired by Maxygen in 2000), Aeglea Biotherapeutics in 2013 (NASDAQ: AGLE) and Kyn Therapeutics Inc. in 2016 (renamed Ikena Oncology, NASDAQ: IKNA). It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. Compared to these stocks Citizens & Northern Corporation (NASDAQ:CZNC) is even less popular than FDUS. Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. We specialize in metabolism and enzymology-based discovery to generate innovative therapies that can modulate the chemical imbances that drive disease. Aeglea BioTherapeutics has raised a total of $56M in funding over 2 rounds. There are 2 companies in the Aeglea Biotherapeutics, Inc. corporate family. Aeglea BioTherapeutics to Participate in September Investment Conferences. Their latest funding was raised on Mar 23, 2015 from a Series B round. Aegle Therapeutics is developing a first in class therapy using extracellular vesicles, including exosomes, secreted by allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions including dystrophic epidermolysis bullosa, a rare pediatric blistering disease. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Thursday, March 18, 2021. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) was in 19 hedge funds' portfolios at the end of the second quarter of 2020. Aeglea BioTherapeutics is registered under the ticker NASDAQ:AGLE . Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. The HR person was knowledgeable about the role. Get the latest Aeglea Bio Therapeutics Inc (AGLE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Aeglea BioTherapeutics (AGLE): Q1 GAAP EPS of -$0.28 misses by $0.14.Cash, cash equivalents, marketable securities and restricted cash of $128.5M Analyst Ratings. I have been working at Aeglea BioTherapeutics full-time for more than a year. Aeglea BioTherapeutics revenue from 2015 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Key Data Points. AUSTIN, Texas — Aeglea Biotherapeutics Inc. (AGLE) on Monday reported a loss of $18.2 million in its first quarter. Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. Find the latest Aeglea BioTherapeutics, Inc. (AGLE) stock quote, history, news and other vital information to help you with your stock trading and investing. Read More. The chart on this page features a breakdown of the total annual pay for Suzanne Bruhn, Ph.D. at AEGLEA BIOTHERAPEUTICS INC as reported in their proxy statements.. Fees Earned or Paid in Cash: This is the amount of fixed retainers and meeting fees and paid in the form of cash. Find real-time AGLE - Aeglea Bio Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East PR Newswire - PRF. Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Read More. Aeglea is a clinical-stage biotechnology company that engineers next-generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. 52wk Range: It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. Aeglea is a clinical stage biopharma led by its CEO, Anthony Quinn, developing enzyme therapeutics to treat metabolic diseases like Arginase 1 Deficiency. The timeline was as described. 08:30 AM ET. Great people, challenging work, good ability to make a personal impact, plenty of growth opportunities. Aeglea BioTherapeutics. Their stock opened with $10.00 in its Apr 7, 2016 IPO. stock was originally listed at a price of $9.77 in Apr 7, 2016. Viewing 1 - 4 of 4 English Reviews. Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with … Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Aeglea BioTherapeutics is funded by 12 investors. Aeglea is an Austin-based company developing human enzyme therapeutics to treat rare metabolic diseases like Arginase 1 Deficiency and Homocystinuria. … Aeglea… Aeglea BioTherapeutics is a biotherapeutic company exploiting the amino acid (AA) dependencies of many tumors by developing novel, human-derived AA-degrading enzymes which have been engineered to have optimized catalytic and biopharmaceutic properties. GlobeNewswire. Aeglea is a biotechnology company focused on the development of novel medicines for rare metabolic disorders. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. Aeglea Biotherapeutics (AGLE) Gets a Buy Rating from H.C. Wainwright. Christopher DAIGE, Director, Biology | Cited by 1,766 | of Aeglea BioTherapeutics, Texas | Read 16 publications | Contact Christopher DAIGE Cons. Still a small company, but they are making strides to become a great company. Item 1.01 Entry into a Material Definitive Agreement. Aeglea BioTherapeutics is a biotherapeutic company exploiting the amino acid (AA) dependencies of many tumors by developing novel, human-derived AA-degrading enzymes which have been engineered to have optimized catalytic and biopharmaceutic properties. Sell Ratings. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. Aegle Therapeutics is developing a first in class therapy using extracellular vesicles, including exosomes, secreted by allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions including dystrophic epidermolysis bullosa, a rare pediatric blistering disease. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to … At Aeglea BioTherapeutics Inc., we promise to treat your data with respect and will not share your information with any third party. Interview. Pros. Aeglea BioTherapeutics Inc. SEC filings breakout by MarketWatch. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) is the most popular stock in this table. Overall the process flowed very well. Aegle Therapeutics. Aeglea BioTherapeutics Inc. SEC filings breakout by MarketWatch. Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency 05/03/2021 Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency 04/01/2021 About Aeglea BioTherapeutics. Market Cap: $322M. More Details. Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as … Description: Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people … The company was founded in 2013 and is based in Austin, Texas. Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. Earnings are forecast to decline by an average of 2.1% per year for the next 3 years. Great people, challenging work, good ability to make a personal impact, plenty of growth opportunities. Dec 1, 2020 Aeglea Gets FDA Rare-Pediatric Designation for ACN00177 in Homocystinuria Dow Jones Newswires. Recommends. President and CEO Anthony Quinn states that they are reimagining the science of human enzymes in order to address rare genetic diseases. Æglea BioTherapeutics is a biotherapeutic company exploiting the amino acid (AA) dependencies of many tumors by developing novel, human-derived AA-degrading enzymes that have been engineered to have optimized catalytic and biopharmaceutic properties. Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics. This is a breakdown of current recommendations and price targets for uniQure and Aeglea BioTherapeutics, as reported by MarketBeat.com. Description. Aeglea BioTherapeutics is a clinical stage company developing enzyme therapies for rare metabolic diseases like Arginase 1 Deficiency and Homocystinuria. Recommends. Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. View the AGLE U.S. Securities and Exchange Commission reporting information. It specializes in the field of amino acid metabolism to … Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. 5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $12.15 Million for the same. Aeglea BioTherapeutics develops treatments for inborn errors of metaboli® and cancer. I have been working at Aeglea BioTherapeutics full-time for more than a year. He believes their edge is their expertise in human enzymes along with a disease selection approach focusing on validated metabolite targets amenable to modification using human enzyme scaffold and using disease models t… Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company.

Avepoint Teams Migration, Word For Shouting In Happiness, Assumption Church Live Mass, Leonardo Da Vinci Techniques, Whistle Stop Cafe Alberta, Bavarian Edge Replacement Parts, Kevin Durant Average Points Per Game 2021, Dumbbell Exercises For Tennis Players, Fortnite Cloud Gaming,